Therefore, we aimed to assess their impact on the regression of portal hypertension, as assessed by changes in (I) hepatic venous pressure gradient (HVPG) and (II) non-invasive markers (LSM, VWF, VITRO score) as well as (III) clinical events in CHC patients with ACLD who achieved SVR to IFN-free therapies. The gene discussed is VWF; the disease is cryohydrocytosis.